Publications
September 27, 2023 ||
AACR: T cell responses and clinical outcomes in pancreatic and colorectal cancer patients with Minimal Residual Disease in AMPLIFY-201, a Phase 1 trial of a first-in-class Amphiphile lymph node targeted mutant KRAS vaccine.
Scientific Poster » Read more
August 8, 2023 ||
Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice
Nature Communications. Dasari, et. al. » Read more
July 19, 2023 ||
Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity
Cell, Ma et. al » Read more
July 10, 2023 ||
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer
Nature Cancer, Mota, et. al. » Read more
June 3, 2023 ||
ASCO: AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk with KRAS G12D- or G12R-mutated pancreatic and colorectal cancer
Scientific Poster » Read more
November 3, 2022 ||
A Lymph Node Targeted Adjuvant and Engineered Subunit Vaccine Promotes Potent Immunity to Epstein-Barr Virus in HLA-expressing Mice
Research Square, Dasari, et. al. » Read more
October 28, 2022 ||
Amphiphile-CpG vaccination induces potent lymph node activation and COVID-19 immunity in mice and non-human primates
NPJ Vaccines, Seenappa, et. al. » Read more
July 20, 2022 ||
Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity
Scientific Translational Medicine, Hartwell, et. al. » Read more
July 6, 2022 ||
A lymph node targeted protein subunit vaccine generates strong cellular and crossreactive humoral immunity against SARS-CoV-2 with potent long-term recall responses
Scientific Poster » Read more
July 6, 2022 ||
A Lymph Node Targeted Protein Subunit Vaccine Induces Robust Cellular and Humoral Immunity to SARS-CoV-2 in Non-human Primates
Scientific Poster » Read more
July 6, 2022 ||
A Lymph Node Targeted Engineered Subunit Antigen and Molecular Adjuvant Vaccine Promotes Potent Cellular and Humoral Immunity to Epstein Barr Virus in HLA expressing Mice
Scientific Poster » Read more
July 6, 2022 ||
A lymph node targeted CpG, TLR9 agonist induces potent activation of lymphaticinnate immune responses resulting in robust cellular and humoral immunity to SARS-CoV-2
Scientific Poster » Read more
June 6, 2022 ||
TPS2701: First in human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with Kirsten Rat Sarcoma (KRAS) mutated pancreatic ductal adenocarcinoma and other solid tumors (trial in progress)
Scientific Poster » Read more
May 5, 2022 ||
Lymph node-targeted vaccine boosting of TCR-T cell therapy enhances anti-tumor function and eradicates solid tumors
BioRxIV, Drakes, et. al. » Read more
April 29, 2022 ||
Lymph-Node Targeted Boosting with Cognate Amphiphile-Peptide Vaccines Enhances TCR-T Cell Therapy to Eradicate Solid Tumors
Presentation — Keystone Emerging Cellular Therapies Conference 2022, Dylan Drakes, PhD » Read more
March 29, 2022 ||
A Lymph-node Targeted Protein Subunit Vaccine Induces Potent and Cross-reactive Cellular and Humoral Immunity to COVID-19 in Mice and Non-Human Primates
Presentation — Vaccine Summit Boston 2022, Pete DeMuth, PhD » Read more
March 23, 2022 ||
Lymph-Node Targeted TLR9 Agonists Enable Potent Cellular Immune Responses Against Cancer & Infectious Disease
Presentation — STING & TLR — Targeting Therapies Summit 2022, Pete DeMuth, PhD » Read more
November 12, 2021 ||
Drakes Dylan Lymph node targeted cognate amphiphile-peptide vaccines enhances tcr-t therapy
Audio recording » Read more
November 12, 2021 ||
Lymph Node Targeted Boosting with Cognate Amphiphile-Peptide Vaccines Enhances TCR-T Cell Therapy to Eradicate Solid Tumors
Scientific Poster » Read more
November 12, 2021 ||
Amphiphile-Peptide Boosting with FMC63-binding Surrogate Peptide Mimotopes Induces Activation and Potent Effector Function in CAR-T Cells Targeting CD19
Scientific Poster » Read more
September 22, 2021 ||
Vaccination with a lymph node targeted Amphiphile‐CpG adjuvant promotes potent cellular and humoral immunity to SARS‐CoV‐2 protein subunit antigens
Peter DeMuth, PhD, Vice President of Research — Vaccines Summit 2021 » Read more
September 9, 2021 ||
Approaches to Improve the Clinical Performance of Genetically Engineered T Cells
July 10, 2021 ||
Combined PET and Whole Tissue Imaging of Lymphatic Targeting vaccine in NHPs
Antigen accumulation in lymph nodes (LNs) is critical for vaccine efficacy, but understanding of vaccine biodistributionin humans or large animals remains limited. » Read more
March 19, 2021 ||
Exploiting albumin as a mucosal vaccine chaperone for robust generation of lung-resident memory T cells
Tissue-resident memory T cells (TRMs) can profoundly enhance mucosal immunity, but parameters governing TRM induction by vaccination remain poorly understood. » Read more
February 2, 2021 ||
A lymph node–targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2
Science Advances Martin P. Steinbuck, Lochana M. Seenappa, Aniela Jakubowski, Lisa K. McNeil, Christopher M. Haqq*, Peter C. DeMuth The profound consequences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mandate urgent development of effective vaccines. Here, we evaluated an Amphiphile (AMP) vaccine adjuvant, AMP-CpG, composed of diacyl lipid–modified CpG, admixed with the SARS-CoV-2 Spike-2 receptor […] » Read more
October 2, 2020 ||
World Vaccine Congress: A lymph node targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2
The SARS-CoV-2 pandemic’s public health, economic, and social impacts mandate urgent development of effective vaccines to contain or eradicate infection. To that end, we evaluated a novel amphiphile (AMP) vaccine adjuvant, AMP-CpG, composed of diacyl lipid-modified CpG, admixed with the SARS-CoV-2 Spike-2 receptor binding domain (Spike RBD) protein for immunization (ELI 005). » Read more
September 15, 2020 ||
RAS Summit: Targeting the lymph nodes to enhance mutant KRAS-specific vaccine responses
August 18, 2020 ||
A lymph node targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2
The SARS-CoV-2 pandemic has led to public health, economic, and social consequences that mandate urgent development of effective vaccines to contain or eradicate infection. To that end, we evaluated a novel amphiphile (AMP) vaccine adjuvant, AMP-CpG, composed of diacyl lipid-modified CpG, admixed with the SARS-CoV-2 Spike-2 receptor binding domain protein as a candidate vaccine (ELI-005) […] » Read more
July 14, 2020 ||
A lymph node targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2
June 2, 2020 ||
Orchestrating the immune system for precision immunity — Elicio’s lymph node-targeting Amphiphile technology delivers potent T cell activation and boosts the effects of engineered cell therapies
Immune cells are naturally gifted in recognizing antigens and fighting off infection and disease. But, just like talented people, they need nurturing and the right training to fulfil their true potential. For immune cells this means a spell in lymph nodes— the training camps of the immune system—where they receive specialized instruction in the art of immune surveillance and attack. » Read more
July 11, 2019 ||
Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor
September 10, 2018 ||
Enhancement of peptide vaccine immunogenicity by increasing lymphatic drainage and boosting serum stability cancer immunology research
Antitumor T-cell responses have the potential to be curative in cancer patients, but the induction of potent T-cell immunity through vaccination remains a largely unmet goal of immunotherapy. » Read more
October 24, 2016 ||
Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses
Nature Medicine » Read more
February 16, 2014 ||
Structure-based programming of lymph-node targeting in molecular vaccines
Nature » Read more